Merck SG&A Expenses 2012-2026 | MRK

Merck sg&a expenses for the twelve months ending March 31, 2026 were $10.880B, a 0.05% decline year-over-year.

  • Merck annual sg&a expenses for 2025 were $10.733B, a 0.77% decline from 2024.
  • Merck annual sg&a expenses for 2024 were $10.816B, a 2.97% increase from 2023.
  • Merck annual sg&a expenses for 2023 were $10.504B, a 4.6% increase from 2022.

Merck SG&A Expenses 2012-2026 | MRK

  • Merck annual sg&a expenses for 2025 were $10.733B, a 0.77% decline from 2024.
  • Merck annual sg&a expenses for 2024 were $10.816B, a 2.97% increase from 2023.
  • Merck annual sg&a expenses for 2023 were $10.504B, a 4.6% increase from 2022.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$887.6B
Johnson & Johnson (JNJ)$574.4B
AbbVie (ABBV)$367.7B
Roche Holding AG (RHHBY)$318.8B
Novartis AG (NVS)$294B
Novo Nordisk (NVO)$167.5B
Pfizer (PFE)$153.1B
Sanofi (SNY)$114B
Bayer (BAYRY)$46.2B
Innoviva (INVA)$1.8B